Video Experimental Relacionado

Updated: Jan 8, 2026

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Patrones de eventos adversos relacionados con el sistema inmunitario en pacientes tratados para diversos tipos de

Matthew J Slaught¹, Dalia Kaakour², Armon Azizi¹

¹University of California Irvine School of Medicine, Irvine, CA, USA.

Future oncology (London, England)

|December 21, 2025

Abstracto

Aims:

To investigate the association between primary cancer type and the tissues affected by immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors (ICIs).

Patients & Methods:

A retrospective chart review was conducted on 241 patients representing 262 treatment lines involving ICIs at a single institution.

Results:

No significant association was found between cancer type and tissue-specific irAEs. irAE incidence was higher with combination PD-1/CTLA-4 inhibitors vs. PD-1 inhibitors alone (61% vs. 46%, p = 0.042). Median time to first irAE was 7.88 months for PD-1 monotherapy versus 2.30 months for combination therapy (log-rank p = 0.00011), a difference of 5.58 months.

Conclusions:

Primary cancer type was not significantly associated with tissue-specific irAEs in ICI-treated patients. The 5.58-month difference in median time to irAE onset has important implications for monitoring protocols. Further research is needed to identify factors predicting irAE patterns and severity.

Palabras clave:

inhibidores de CTLA-4 inhibidores de puntos de control inmunitario inhibidores de PD-1 inmunoterapia contra el cáncer inmunoterapia combinada eventos adversos relacionados con el sistema inmunitario estudio de cohorte retrospectivo

Más Videos Relacionados

High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research

High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research

Published on: June 10, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Videos de Conceptos Relacionados

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...